India Pharma Outlook Team | Tuesday, 28 October 2025
Sai Life Sciences Limited, among India's fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO), is announcing the ground breaking of a CMC Process R&D Center at its integrated R&D campus in Hyderabad.
The facility is expected to be completed by September 2026 and will double the company's Process R&D capacity, while offering additional process R&D in peptide development, oligo intermediates & linkers development, formulation development and early phase clinical supply services.
Also Read: Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings
Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: "As our partners seek greater speed, flexibility, and scientific depth, we are scaling our capabilities to move programs faster and more efficiently through the development continuum. In an environment where timelines are continually compressing, this new center enhances our ability to combine scientific excellence with execution agility."
The new CMC Process R&D Center is a strategic investment in scale, sustainability and specialization. The new R&D Center will offer support for Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models, enabling flexible collaboration with global innovators-from early development through to late stage CMC programs.
This engagement model will further bolster Sai Life Sciences' preferred partner position for integrated drug development, attesting to the growing global demand for end-to-end, partnership driven solutions, and delivery of quality and timelines. This investment is a part of the company's planned capital expenditure, and is a testament to the strong business momentum and expanding partnership with global pharmaceutical and biotech partners.
The capex is guided by growing demand for larger clinical-scale programs, a robust late-stage development pipeline, and the need for scalable capacity across CMC development and manufacturing.
.jpg)
